Head-To-Head Contrast: Stryker (SYK) & Uroplasty (UPI)
Stryker (NYSE: SYK) and Uroplasty (NASDAQ:UPI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.
Stryker pays an annual dividend of $1.88 per share and has a dividend yield of 1.2%. Uroplasty does not pay a dividend. Stryker pays out 70.1% of its earnings in the form of a dividend. Stryker has raised its dividend for 7 consecutive years.
Stryker has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Uroplasty has a beta of -1.26, meaning that its stock price is 226% less volatile than the S&P 500.
This table compares Stryker and Uroplasty’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Stryker and Uroplasty, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Stryker currently has a consensus target price of $162.32, indicating a potential upside of 0.38%. Given Stryker’s higher possible upside, analysts clearly believe Stryker is more favorable than Uroplasty.
Earnings and Valuation
This table compares Stryker and Uroplasty’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Stryker||$12.44 billion||4.87||$1.02 billion||$2.68||60.34|
Stryker has higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
74.5% of Stryker shares are held by institutional investors. 7.4% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Stryker beats Uroplasty on 13 of the 14 factors compared between the two stocks.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.